ADULT AIDS CLINICAL TRIALS UNIT

在1991年的ACTG重新竞争中，康奈尔大学的独立ACTU University Medica College（CMEC）和Memorial Sloan-Kettering Cancer Center （MSKCC）已选择合并为一个主要ACTU，并增加两个新的子单位， 圣位于曼哈顿的克莱尔医院和位于纽约的北岸大学医院 长岛 MSKCC也在申请病毒学和药理学核心 Laboratories. 联合国难民事务高级专员办事处和MSKCC ACTU的合并将提供关键 （a）精简和合并ACTU的共享活动，（B） 提高成本效益，同时保持登记，和（c）合理 在一个中心集中和指导高优先级试验， 公认的临床专业知识或最佳的专用临床设施。 增加了圣克莱尔医院（东海岸最活跃的艾滋病毒单位） 和北岸作为次级单位，将增加妇女、少数民族、 IVDU和囚犯将ACTG网络扩展到新的服务不足的地区 约克市（皇后区）和长岛，并为ACTG提供额外的 艾滋病相关疾病的研究专家。 南极洲委员会和南极洲科学委员会行动单位对《公约》作出了明确的科学贡献， ACTG，并在第一、第二和第三阶段展示了高水平的成就。 艾滋病防治小组三个优先领域的三项议定书： 泌尿系感染（OI）和肿瘤学在OI试验中的入组，CISC- MSKCC在纽约市和全国排名第七， 肿瘤学试验注册人数在纽约市排名第一， 全国范围内。 保持这种高水平的参与开放式倡议， 肿瘤学研究将是新的CNC-MSKCC ACTU的主要目标 及其下属单位。 除了大量的内源性患者人群外， 已经在主要的CSC-MSKCC ACTU站点和两个子单元（都是 纽约州指定艾滋病护理单位），40多个独立的联系点 也将用作试验患者的来源，明确强调 招募代表性不足的群体。 其他特别重要的 新的CNOC-MSKCC ACTU的组成部分包括一个新的大型（专用） 门诊部、支持性GCRC、熟练掌握OI的研究者和 肿瘤试验，一个活跃的社区咨询委员会，和护理， 行政、数据管理和药房工作人员经验丰富 ACTG临床试验的工作。 总的来说，CMC-MSKCC及其子单元 为开展高优先级ACTG研究提供了独特的ACTU。

For the 1991 ACTG recompetition, the independent ACTUs at Cornell University Medica College (CUMC) and Memorial Sloan-Kettering Cancer Center (MSKCC) have elected to merge as one Main ACTU and add two new Subunits, St. Clare's Hospital in Manhattan and North Shore University Hospital on Long Island. MSKCC is also applying for Virology and Pharmacology Core Laboratories. The merger of the CUMC and MSKCC ACTUs will provide the key opportunities to (a) streamline and consolidate shared ACTU activities, (b) increase cost efficiency while maintaining enrollment, and (c) rationally focus and direct high priority trials at one site which has either recognized clinical expertise or an optimal dedicated clinical facility. The addition of St. Clare's (the most active HIV Unit on the East Coast) and North Shore as Subunits will enhance accrual of women, minorities, IVDUs, and prisoners, extend the ACTG network to underserved areas of New York City (Queens) and Long Island, and provide the ACTG with additional investigators expert in HIV-related disease. The CUMC and MSKCC ACTUs have made clear scientific contributions to the ACTG, and have demonstrated high-level accomplishments in phase I, II, and III protocols in three ACTG priority areas: Primary HIV Infection, Opportunistic Infections (OI), and Oncology in OI trials enrollment, CUMC- MSKCC together ranks first in New York City and seventh nationally, and in Oncology trials enrollment ranks first in New York City and second nationally. Maintaining this high level of participation in OI and Oncology studies will be the primary objective of the new CUMC-MSKCC ACTU and its Subunits. In addition to the large endogenous patient populations already at the Main CUMC-MSKCC ACTU sites and the two Subunits (both are New York State Designated AIDS Care Units), more than 40 separate linkages will also be used as sources of trials patients with clear emphasis on recruitment of under-represented groups. Other particularly important components of the new CUMC-MSKCC ACTU include a new large (dedicated) outpatient unit, a supportive GCRC, investigators skilled in OI and Oncology trials, an active Community Advisory Board, and nursing, administrative, data management, and pharmacy staffs thoroughly experienced in ACTG clinical trials work. Together, CUMC-MSKCC with its Subunits provides a unique ACTU for conducting high priority ACTG studies.